MedPath

Clinical Trial News

VESPER Trial: BaSq Subtype Linked to Poorer Outcomes in Bladder Cancer

  • The VESPER trial's molecular subtyping analysis reveals the BaSq subtype (pure or mixed) is associated with decreased progression-free survival and overall survival in bladder cancer patients.
  • Patients in the neoadjuvant setting who received dose-dense MVAC chemotherapy showed significantly higher three-year progression-free survival compared to those receiving gemcitabine and cisplatin.
  • Extended follow-up of the VESPER trial demonstrated improved overall survival at 5 years in the dose-dense MVAC group versus the gemcitabine + cisplatin group within the neoadjuvant subgroup.
  • Further research is needed to understand the biological bases for mixed tumors and to improve prognosis for BaSq subtype tumors.

WHO Assesses India's Drug Regulatory Authority and Vaccine Manufacturing

  • The World Health Organization (WHO) has assessed India's Central Drugs Standard Control Organization (CDSCO), the nation's top drug regulator.
  • The evaluation aimed to determine the status of India's National Regulatory Authority (NRA) concerning drug regulation.
  • The assessment also included an evaluation of vaccine manufacturing practices within India, a major global vaccine producer.

Oncology Leaders Emphasize Cautious AI Implementation to Maintain Physician Trust

  • Rocky Mountain Cancer Centers' executive director warns that inaccurate AI outputs could damage physician confidence in the technology for months, emphasizing the need for careful implementation.
  • Healthcare leaders advocate for experimental demonstration projects to understand both AI capabilities and provider responses before widespread adoption in oncology practices.
  • Experts stress the importance of maintaining physician autonomy and accountability while integrating AI tools into cancer care workflows.

Psilocybin Shows Similar Efficacy to Escitalopram in Depression: Phase 2 Trial Follow-up

  • A 6-month follow-up of a phase 2 trial reveals that psilocybin shows similar effectiveness to escitalopram in treating moderate-to-severe major depressive disorder.
  • The study highlights the potential of psilocybin therapy as an alternative treatment paradigm for depression, warranting further investigation.
  • Researchers emphasize the need for varied treatment approaches due to the diverse nature of depression among individuals.
  • The findings are encouraging, especially alongside larger ongoing trials of psilocybin in the UK, Europe, and the US.

Relacorilant and Surgery Improve Hemostatic Markers in Cushing's Syndrome

  • A study shows that hypercoagulopathy, a complication in Cushing's Syndrome (CS), improves with both relacorilant treatment and surgery.
  • Relacorilant, a selective glucocorticoid receptor modulator (SGRM), demonstrated improvements in coagulation markers after 3-4 months of treatment.
  • Surgical intervention also led to improvements in coagulation markers within an average of 6 months post-operation in CS patients.
  • The study suggests relacorilant may offer a beneficial treatment option for CS patients, particularly those at high risk of VTE or not suitable for surgery.

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750CompletedPhase 2
Corcept Therapeutics
Posted 6/1/2016

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198Active, Not RecruitingPhase 2
Corcept Therapeutics
Posted 5/7/2018

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590CompletedPhase 3
Corcept Therapeutics
Posted 7/27/2020

Atezolizumab and Durvalumab Combination Therapies Not Cost-Effective for ED-SCLC in Japan

  • A cost-effectiveness analysis in Japan reveals that atezolizumab and durvalumab, when combined with chemotherapy, are not cost-effective as first-line treatments for extensive-disease small-cell lung cancer (ED-SCLC).
  • The incremental cost-effectiveness ratios (ICERs) for atezolizumab and durvalumab combination therapies significantly exceeded the willingness-to-pay threshold of 15 million JPY per quality-adjusted life year (QALY).
  • Sensitivity analyses suggest that substantial price reductions for atezolizumab and durvalumab would be necessary to achieve cost-effectiveness, but such reductions are unlikely to be feasible.
  • The findings align with previous studies in the USA and China, indicating consistent economic challenges associated with immune checkpoint inhibitor combination treatments for ED-SCLC.

End-of-Dose Phenomena Observed in Multiple Sclerosis Patients on Ofatumumab

  • A study of 103 MS patients found that 34% experienced end-of-dose phenomena (EOD) with ofatumumab, impacting their quality of life.
  • EOD was associated with higher baseline disability, longer disease duration, and older age, highlighting the need for careful monitoring.
  • Fatigue, cognitive impairment, and gait difficulties were the most commonly reported EOD symptoms among patients on ofatumumab.
  • Compared to ocrelizumab, ofatumumab showed a lower incidence of the wearing-off effect in a separate study, suggesting potential differences in B-cell depletion.

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

NCT05701423Active, Not Recruiting
Biogen
Posted 2/8/2023

Psilocybin Shows Promise as Alternative to SSRIs for Depression Treatment

  • A recent study indicates that psilocybin, the active compound in magic mushrooms, offers comparable long-term benefits to escitalopram for treating depression.
  • Psilocybin outperformed escitalopram in enhancing psychosocial functioning, including a greater sense of meaning in life and improved social connectedness.
  • Researchers emphasize that psilocybin is still experimental and should only be administered in controlled environments due to potential risks.
  • Experts caution that not everyone is a candidate for psilocybin treatment, particularly those with a history of psychosis or bipolar disorder.

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200CompletedPhase 2
COMPASS Pathways
Posted 3/1/2019

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921Terminated
Usona Institute
Posted 6/30/2020

Psilocybin for the Treatment of Cluster Headache

NCT02981173CompletedPhase 1
Yale University
Posted 12/5/2016

Ozanimod Shows Sustained Reduction in Brain Atrophy in Relapsing Multiple Sclerosis

  • Long-term data from the DAYBREAK trial shows ozanimod treatment resulted in sustained reductions in brain volume loss (BVL) for up to 5 years in relapsing MS patients.
  • Patients on continuous ozanimod demonstrated stable and low rates of whole brain volume loss compared to those who switched from interferon-beta-1a.
  • Switching to ozanimod from interferon-beta-1a reduced rates of whole brain volume loss and reversed cortical grey matter volume loss trends.
  • After 72 months, ozanimod treatment showed a low adjusted annualized relapse rate, with a majority of patients remaining relapse-free.

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717CompletedPhase 3
Celgene
Posted 10/16/2015

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058CompletedPhase 3
Celgene
Posted 12/3/2014

Stealth BioTherapeutics Presents Preclinical Data on Bevemipretide for AMD

  • Stealth BioTherapeutics presented preclinical data demonstrating bevemipretide's effective retinal delivery via topical ocular administration in age-related macular degeneration (AMD) models.
  • The study showed bevemipretide's protective effects, including mitigating retinal thickness reduction in rats exposed to bright light-induced retinal degeneration.
  • Bevemipretide improved the viability of iPSC-derived retinal pigment epithelial (RPE) cells from AMD patients and reduced mitochondrial reactive oxygen species (ROS) production.
  • Stealth BioTherapeutics plans to initiate clinical studies to further develop topical bevemipretide as a potential disease-modifying therapy for dry AMD.

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731RecruitingPhase 3
Stealth BioTherapeutics Inc.
Posted 5/30/2024

Trending News

1

FDA Approves Streamlined Access for Bristol Myers Squibb CAR T Cell Therapies

2 days ago
2

UCB's Fenfluramine Achieves Positive Phase 3 Results in Ultra-Rare CDKL5 Deficiency Disorder

2 days ago
3

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

3 days ago
4

ProFound Therapeutics Partners with Novartis in $775M Cardiovascular Drug Discovery Deal

2 days ago
5

Percheron Therapeutics Acquires Phase II-Ready Anti-VISTA Cancer Immunotherapy HMBD-002 in $290M Deal

3 days ago
6

Lipocine Initiates Phase 3 Trial for Oral Brexanolone in Postpartum Depression

2 days ago
7

China Approves First Once-Daily Nebulized LAMA for COPD, Triggering $7.5M Milestone for Theravance

2 days ago
8

FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease

a day ago
9

DBV Technologies Initiates COMFORT Toddlers Phase 3 Study for Viaskin Peanut Patch in Young Children

3 days ago
10

Bavarian Nordic Initiates First Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

3 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy